Retatrutide appears to be a new pharmaceutical in the fight against obesity. This novel drug, belonging to a dual GLP-1 and GIP receptor agonist, shows promising results in investigations. By boosting these receptors, Retatrutide controls cravings, {promotesenergy expenditure, and ultimately results in significant weight loss. While research is on